Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Kellbenx Incorported operates within the Biotechnology & Pharmaceuticals technology area. The company's patent portfolio currently features 1 pending office action. This single action represents the current active engagement with the patent office for their pharmaceutical filings.
The prosecution is handled by 1 distinct examiner and 1 distinct art unit. This concentration indicates that the technical content remains within a single regulatory department. This allows for a focused prosecution strategy that accounts for the specific trends of 1 art unit.
KIRWIN, STEFANIE JOHANNA is the busiest examiner, holding 1 busiest examiner pending office action. This examiner is responsible for the only active matter in the portfolio. The immediate success of the company's patent efforts is tied to the review and requirements of this specific individual.
The presence of 1 distinct examiner for 1 pending office action ensures a direct relationship between the examiner and the active workload. This consistency may lead to more predictable prosecution timelines. Practitioners can focus their efforts on the specific requirements of KIRWIN, STEFANIE JOHANNA.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIRWIN, STEFANIE JOHANNA | 1 | 15.6% | +29.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18175224 | FILTRATION-BASED METHODS FOR PREPARING FETAL NUCLEATED RED BLOOD CELLS (NRBCS) FOR DIAGNOSTIC TESTING | KIRWIN, STEFANIE JOHANNA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18175224 | FILTRATION-BASED METHODS FOR PREPARING FETAL NUCLEATED RED BLOOD CELLS (NRBCS) FOR DIAGNOSTIC TESTING | KIRWIN, STEFANIE JOHANNA | — |
| Art Unit | Apps |
|---|---|
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18175224 | FILTRATION-BASED METHODS FOR PREPARING FETAL NUCLEATED RED BLOOD CELLS (NRBCS) FOR DIAGNOSTIC TESTING | KIRWIN, STEFANIE JOHANNA | 1684 | §103 | Non-Final OA | — | Pending | Feb 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKellbenx Incorported has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Stefanie Johanna Kirwin has the most, with 1 of Kellbenx Incorported's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
